Roche's (ROP SW) obesity product development head says the latest obesity drug results are reassuring, is confident that enicepatide will achieve higher weight loss in new studies
#SOFTWARE#EQUITIES#EU SESSION#US SESSION#APPLICATION SOFTWARE#SOFTWARE & SERVICES#S&P 500 INDEX#NASDAQ 100 INDEX#ROPER TECHNOLOGIES INC#ROP#SMI